| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.91 [0.83, 1.00] | | < 1 | | 23% | 7 studies (7/-) | 98.0 % | some concern | serious | moderate | crucial | - |
| progression or deaths (PFS) | 1.23 [0.94, 1.63] | | < 1 | | 93% | 7 studies (7/-) | 6.8 % | some concern | serious | moderate | important | - |
| DCR | 0.49 [0.30, 0.81] | | > 1 | | 64% | 2 studies (2/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
| irORR | 0.24 [0.03, 2.19] | | > 1 | | 0% | 1 study (1/-) | 10.3 % | NA | not evaluable | | non important | - |
| irPFS | 1.44 [1.09, 1.91] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.86 [0.48, 1.53] | | > 1 | | 91% | 6 studies (6/-) | 30.4 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.74 [0.33, 1.67] | | < 1 | | 51% | 3 studies (3/-) | 76.5 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.47 [0.10, 2.17] | | < 1 | | 98% | 3 studies (3/-) | 83.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.24 [0.67, 2.31] | | < 1 | | 0% | 3 studies (3/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.53 [0.16, 1.78] | | < 1 | | 94% | 3 studies (3/-) | 84.7 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.26 [0.86, 1.83] | | < 1 | | 0% | 1 study (1/-) | 11.9 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.31 [0.54, 3.21] | | < 1 | | 85% | 2 studies (2/-) | 27.5 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.80 [1.33, 2.44] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.57 [0.24, 1.33] | | < 1 | | 96% | 7 studies (7/-) | 90.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.62 [0.21, 1.80] | | < 1 | | 97% | 5 studies (5/-) | 81.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.92 [0.75, 4.94] | | < 1 | | 0% | 5 studies (5/-) | 8.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.72 [0.25, 2.01] | | < 1 | | 91% | 5 studies (5/-) | 73.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.12 [1.55, 2.90] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.50 [0.08, 3.03] | | < 1 | | 0% | 4 studies (4/-) | 77.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.46 [0.15, 1.40] | | < 1 | | 89% | 5 studies (5/-) | 91.4 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.54 [0.25, 1.15] | | < 1 | | 24% | 5 studies (5/-) | 94.5 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.73 [0.09, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.87 [0.03, 25.93] | | < 1 | | 61% | 2 studies (2/-) | 53.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.57 [0.26, 1.27] | | < 1 | | 46% | 6 studies (6/-) | 91.4 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.73 [0.31, 1.73] | | < 1 | | 63% | 6 studies (6/-) | 76.4 % | some concern | not evaluable | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 0.73 [0.09, 6.31] | | < 1 | | 0% | 2 studies (2/-) | 61.0 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 4.01 [0.37, 43.00] | | < 1 | | 2% | 2 studies (2/-) | 12.7 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.81 [0.36, 1.81] | | < 1 | | 64% | 6 studies (6/-) | 69.7 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.73 [1.04, 2.86] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.81 [0.97, 3.36] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.97 [0.36, 10.94] | | < 1 | | 0% | 4 studies (4/-) | 22.0 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.95 [0.82, 4.61] | | < 1 | | 0% | 2 studies (2/-) | 6.5 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.97 [0.38, 2.48] | | < 1 | | 0% | 2 studies (2/-) | 52.2 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.74 [0.36, 8.39] | | < 1 | | 50% | 2 studies (2/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.95 [0.09, 10.52] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 2.43 [0.23, 25.98] | | < 1 | | 34% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.20 [0.01, 4.07] | | < 1 | | 77% | 2 studies (2/-) | 85.1 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 0.79 [0.02, 40.48] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.62 [0.28, 1.36] | | < 1 | | 45% | 6 studies (6/-) | 88.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.25 [0.08, 0.74] | | < 1 | | 88% | 5 studies (5/-) | 99.4 % | some concern | serious | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.87 [0.28, 2.71] | | < 1 | | 54% | 4 studies (4/-) | 59.8 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.28 [0.74, 2.22] | | < 1 | | 2% | 5 studies (5/-) | 19.0 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 1.33 [0.50, 3.53] | | < 1 | | 10% | 2 studies (2/-) | 28.5 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.90 [0.09, 8.74] | | < 1 | | 0% | 3 studies (3/-) | 53.4 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.20 [0.14, 10.36] | | < 1 | | 0% | 3 studies (3/-) | 43.3 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 5.92 [0.71, 49.31] | | < 1 | | 0% | 1 study (1/-) | 5.1 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 13.96 [1.83, 106.45] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.36 [1.79, 10.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.34 [0.02, 6.97] | | < 1 | | 77% | 2 studies (2/-) | 75.7 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.00 [0.38, 2.62] | | < 1 | | 46% | 3 studies (3/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.61 [0.32, 1.17] | | < 1 | | 22% | 5 studies (5/-) | 93.2 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.44 [0.06, 3.49] | | < 1 | | 36% | 3 studies (3/-) | 77.9 % | some concern | not evaluable | moderate | non important | - |
